You are here
Comabella, Manuel
Neurologist. Head of Neuroimmunology Laboratory
President of the BioMSeu (European Consortium for CSF Biomarker Research), 2015
Member of the Steering Committee of the BioMSeu (European Consortium for CSF Biomarker Research), 2013-2015
Academic editor of the PLoS ONE journal, 2014
Member of the Internal Scientific Committee of the Spanish Society of Neurology (SEN), 2014
Member of the Steering Committee of the European School of Neuroimmunology (ESNI), 2013
Member of the Intern Scientific Committee at the Institut de Recerca Hospital Vall d’Hebron Foundation, Universitat Autònoma de Barcelona, 2013
Neurosciences coordinator at the Institut de Recerca Hospital Vall d’Hebron Foundation, Universitat Autònoma de Barcelona, 2013
Member of the editorial board of Multiple Sclerosis Journal, 2013
Member of the editorial board of Journal of Neuroimmunology, 2009
Member of the International MS Genetics Consortium strategic group (IMSGC), 2008
Education
Degree in Medicine and Surgery, Universitat Central de Barcelona
Residency in Neurology, Vall d’Hebron University Hospital
Research fellowship in neuroimmunology, Brigham and Women's Hospital - Center for Neurologic Diseases, Harvard Medical School, Boston (US)
Phd in Medicine, Universitat Autònoma de Barcelona
Career
Merck Serono Research Grant Award 2016: Clinical Research in the Multiple Sclerosis area
Neurological Diseases Award of the Spanish Society of Neurology, scientific modality, 2014
NOVARTIS Award: best published work about demyelinating diseases (Spanish Society of Neurology, 2013)
NOVARTIS Award: best oral communication about demyelinating diseases (Spanish Society of Neurology, 2013)
Editor of a special edition of Journal of Neuroimmunology: “New technologies for biomarker discovery in MS” (2013)
Editor of a special edition of Journal of Clinical Immunology: “Therapeutic strategies in multiple sclerosis” (2012)
BIOGEN IDEC Award: best published work about demyelinating diseases (Spanish Society of Neurology, 2011)
Merck Serono Research Grant Award 2010: Clinical Research in the Multiple Sclerosis area
Diario Médico Award (“Diario Médico best ideas”) for the press release titled “A region of chromosome 13 affects the risk of MS”, 2009
Projects / Lines of Research / Interests
From a translational approach, the basic research developed by the group is focused on these two lines: (I) identification of molecular biomarkers related to different aspects of multiple sclerosis, mainly pronostic biomarkers in the early stages of disease; (II) development of new treatments in clinical practice.
Bio
Comabella M, Cantó E, Nurtdinov R, Río J, Villar LM, Picón C, Castilló J, Fissolo N, Aymerich X, Auger C, Rovira A, Montalban X. MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Hum Mol Genet. 2016 Jan 15;25(2):308-16.
Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-Martín E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, García-Merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015 Apr;138(Pt 4):918-31.
Malhotra S, Río J, Urcelay E, Nurtdinov R, Bustamante MF, Fernández O, Oliver B, Zettl U, Brassat D, Killestein J, Lechner-Scott J, Drulovic J, Chan A, Martinelli-Boneschi F, García-Merino A, Montalban X, Comabella M. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. Brain. 2015 Mar;138(Pt 3):644-52.
Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014 Jan;13(1):113-26.
Comabella M, Caminero AB, Malhotra S, Agulló L, Fernández O, Reverter F, Vandenbroeck K, Rodríguez-Antigüedad A, Matesanz F, Izquierdo G, Urcelay E, López-Larios A, Sánchez A, Otero S, Tintoré M, Montalban X. TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology. 2013 May 28;80(22):2010-6.
Bustamante MF, Fissolo N, Río J, Espejo C, Costa C, Mansilla MJ, Lizasoain I, Moro MA, Carmen Edo M, Montalban X, Comabella M. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis. Ann Neurol. 2011 Oct;70(4):634-45.
Chan A, Pirmohamed M, Comabella M. Pharmacogenomics in neurology: current state and future steps. Ann Neurol. 2011 Nov;70(5):684-97.
Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, Julià E, Rovira A, Cantó E, Alvarez-Cermeño JC, Villar LM, Tintoré M, Montalban X. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010 Apr;133(Pt 4):1082-93.
Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H, Caballero E, Münz C, Montalban X, Comabella M. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol. 2010 Feb;67(2):159-69.
Camiña-Tato M, Morcillo-Suárez C, Bustamante MF, Ortega I, Navarro A, Muntasell A, López-Botet M, Sánchez A, Carmona P, Julià E, Tortola MT, Audí L, Oksenberg JR, Martin R, Montalban X, Comabella M. Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. J Immunol. 2010 Nov 1;185(9):5392-404.
Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009 Dec;132(Pt 12):3353-65.
Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, Martin R, Montalban X. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. 2009 Aug;66(8):972-8.
